Stem cells have been extensively investigated as tumour-tropic vectors for gene delivery to solid tumours. In this review, we discuss the potential for using stem cells as cellular vector systems in gene therapy for malignant gliomas, with a focus on neural stem cells, and multipotent mesenchymal stromal cells. Tumour cell-derived substances and factors associated with tumour-induced inflammation and tumour neovascularisation can specifically attract stem cells to invasive gliomas. Injected stem cells engineered to produce anti-tumour substances have shown strong therapeutic effects in experimental glioma models. However, the potential caveats include the immunosuppressive functions of multipotent mesenchymal stromal cells, the contribution of stem cells to the pro-tumorigenic stroma, and the malignant transformation of implanted stem cells. In addition, it is not yet known which stem cell types and therapeutic genes will be most effective for the treatment of glioma patients. Here, we highlight the possibilities and problems for translating promising experimental findings in glioma models into the clinic.
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INTRODUCTION
Glioblastoma (GBM) is the most common and severe form of malignant glioma. Despite enormous efforts, the prognosis for GBM patients is still poor. The median survival of GBM patients is 14,6 months, and around 10% of GBM patients survive more than 5 years, despite receiving surgery, radiotherapy, and chemotherapy with temozolomide (TMZ) 1, 2 . A major portion of treatment failure is due to the invasive growth of GBM. Microscopic tumour extensions and distant tumour microsatellites grow along white matter fibre tracts and normal brain tissue blood vessels 3 . Therefore, complete surgical resection is rarely achieved. Other GBM therapy challenges include an increased interstitial fluid pressure within the tumour, resulting in low concentrations of systemically delivered drugs, an intrinsic and acquired drug resistance of tumour cells, and treatment neurotoxicity 4 . Furthermore, although GBM presents with a dysfunctional and leaky blood-brain barrier (BBB), single infiltrative GBM cells reside deep within the normal brain parenchyma with an intact BBB; therefore, they are protected from many blood-borne drugs 5 . A successful GBM treatment requires several criteria to be fulfilled, including the targeting of invasive tumour cells, the targeting of tumour cells characterised by different genetic aberrations (including putative cancer stem cells), and the selective elimination of tumour cells while sparing normal neural cells 6 .
In this review, we present the concept of using genetically engineered stem cells in gene therapy for brain tumours. We discuss different stem cell types that are used for glioma gene therapy, mechanisms by which stem cells are attracted to tumours, and the major principles of their therapeutic functions. We also highlight critical issues for translating the experimental findings to the clinic.
SCIENTIFIC RATIONALE FOR STEM CELL-BASED THERAPY FOR GBM
Gene therapy using viral vectors has been explored in several clinical GBM treatment trials 7 .
Proteins aimed at inhibiting tumour angiogenesis, enhancing anti-tumour immune responses, and correcting tumour-specific genetic defects have been expressed in GBM by using locally or systemically administered viral gene vectors. Viral-mediated GBM gene therapy has shown promising results in animal models 8 . However, clinical studies have had modest success at limiting tumour growth and extending patient survival 7 . Failure has been attributed mainly to difficulties in achieving the distribution of viral vectors throughout the invasive tumour. In addition, the viral transduction efficiency of GBM cells has been low 7 . Implanting or injecting stem or progenitor cells that have been genetically modified to produce anti-tumour substances has several advantages over viral-vector mediated gene delivery. Initially described by Aboody et al., implanted neural stem cells (NSCs) possess the capacity to migrate to and within intracranial tumours in which the NSCs deliver a cytotoxic substance that can reduce tumour growth 9 . The tumour-tropic homing and migratory capacity has been replicated by many groups using different types of stem/progenitor cells, including multipotent mesenchymal stromal cells (MSCs) 10, 11 , and hematopoietic progenitor cells (HPCs) 12 in animal models. For example, a single MSC implantation into an invasive rat glioma results in MSC migration to the majority of the infiltrative tumour extensions and a fraction of distant tumour microsatellites 13 . Differentiated cells, such as fibroblasts, do not exhibit a similar tumour tropism [9] [10] [11] [12] . In contrast to viral vectors, stem cells are attracted primarily to tumour tissue, whereas they show minimal tropism for normal neural cells.
Therefore, tumour-specific gene delivery is feasible, and cerebral side effects can potentially be avoided 9, 13 . Numerous studies have demonstrated the potential of stem cell vectors in the treatment of brain tumours and many other invasive solid tumour types 14 . Thus, although each tumour type may require tailor-made cellular vehicles and transgenes, the results from work with non-neural tumours may contribute to the development of a successful stem cell therapy for GBM and vice versa.
DIFFERENT TYPES OF CELL VECTORS

Neural stem cells
NSCs can give rise to neurons, astrocytes, and oligodendrocytes. In the adult rodent brain, NSCs are located mainly within two neurogenic zones: the subependymal zone lining the lateral ventricles and the dentate gyrus of the hippocampus 15 . In vitro, NSCs are cultured and expanded as floating cellular aggregates called neurospheres ( Fig. 1A) . Initial findings demonstrated a tumour-tropic migration of the immortalised murine NSC line C17.2, following implantation into, or at a distance from, the experimental gliomas 9 . Subsequently, immortalised murine or human NSC lines and primary NSCs have been widely used for their tumour-tropic capacity and potential to deliver anti-tumour substances to gliomas [16] [17] [18] [19] [20] [21] [22] [23] ( figure   1B ). An advantage of immortalised NSC lines ( figure 1A) is that they are readily available. A well-characterised NSC line can be cultured and expanded in vitro to obtain high numbers of cells ready for transplantation within a short period. In contrast, although it is possible to harvest autologous neural precursor cells from the adult human brain 24 , it could take too long to expand, modify, and characterise these cells to prepare them for implantation into GBM patients. Furthermore, grafting immortalised NSC lines into the brain is associated with two main problems: immunogenicity and tumorigenicity. Immunogenicity implies that the immune system may attack and neutralise the grafted non-autologous cells. This could impair NSC survival and migration to the infiltrative tumour parts, which is crucial for therapeutic function. Immortalised NSCs carrying a proto-oncogene, such as v-myc, may transform and 6 develop into secondary malignancies following implantation into the tumour tissue. It has been reported that a fraction of the NSCs continues to proliferate after implantation or injection to gliomas 9, 23 . In addition, when subjected to growth factors and a tumour microenvironment, normal neural progenitors in the brain can be driven towards malignant masses and potentially contribute to glioma progression 25, 26 . It will be important to determine whether implanted and in vivo proliferating NSCs can form tumorigenic masses after longterm growth in vivo. One way to avoid such an occurrence would be to administer NSCs that are genetically modified to carry a "suicide" gene, such as herpes simplex virus thymidine kinase (HSV-tk). With this approach, it would be possible to eliminate the administered NSCs within the tumours at any given time.
Multipotent mesenchymal stromal cells
Multipotent mesenchymal stromal cells, sometimes called mesenchymal stem cells, are nonhematopoietic stem cells. MSCs are thought to be the precursors of the bone marrow stroma; at a minimum, they can differentiate into chondrocytes, adipocytes, and osteoblasts 27 . MSCs are usually isolated by their adherent growth in culture (figure 1C), differentiation capacity, expression of surface markers (including CD73, CD90, CD105, CD146, CD271, and STRO-1) and lack of expression of the hematopoietic markers CD34 and CD45 27 .
Intracranially implanted or injected mouse, rat, and human MSCs have shown tropism for experimental gliomas in which MSCs can deliver a therapeutic substance leading to an increased survival of the glioma-bearing animals 10, 11 . However, rat MSCs lack the longdistance migratory capacity through normal brain tissue towards the rat glioma when implanted at a distance (i.e., a few millimetres) from the tumour 28 . In contrast, intratumoral implantation of rat MSCs directly into rat gliomas results in an MSC migration to the majority of invasive tumour extensions and a fraction of distant tumour microsatellites 13 ( figure 1D) .
Importantly, the tumour-specific distribution of intratumorally implanted MSC makes the cells well suited for transporting toxic substances specifically into tumours while potentially sparing the normal brain tissue 13 .
MSCs are promising cell therapy candidates because it is easy to obtain MSCs through a bone marrow puncture and, subsequently, to culture and expand the cells in vitro. In principle, this makes it possible to graft autologous MSCs (isolated from the patient). Autologous MSC implantation would avoid graft rejection immunograft issues, but expansion, modification, and characterisation of the MSCs would delay the onset of treatment compared to implantation of a readily available, well-characterised cell line. In addition, there are a number of concerns about the use of MSCs for tumour gene therapy. The findings from other solid tumour types have shown that MSCs may contribute to tumour growth through their immunosuppressive properties, growth factor production, and contribution to the protumorigenic stroma, as well as by the malignant progression of the recruited MSCs, which can drive tumour growth [29] [30] [31] [32] [33] . As part of the tumour microenvironment, MSCs can promote experimental ovarian cancer growth 34 and increase the metastatic capacity of breast cancer cells 35 . In contrast, non-modified MSCs can reduce tumour vascularisation and suppress tumour growth in a malignant melanoma model 36 . Importantly, independent groups have reported that implanted non-modified human or rat MSCs display no glioma-promoting effects 13, 37 . Other findings suggest a glioma-suppressing effect upon implanting human adipose tissue-derived MSCs 38 or bone marrow-derived rat MSCs 11 into gliomas. These divergent results may depend on the differences in the MSC sub-populations (e.g.,
heterogeneity of MSCs within and between the cell cultures leading to functionally different
MSCs in different experiments) 39, 40 and MSC species differences (human MSCs may not necessarily yield the same results as mouse and/or rat MSCs). The conflicting findings of the interaction between MSCs and tumour cells are further reviewed in the literature 41 . The potential risk that human MSCs can undergo transformation into malignant cells under in vitro culture conditions is controversial and reviewed by Prockop et al. 42 .
Alternative types of cellular vectors
Other types of stem and progenitor cells may also serve as migratory vectors to gliomas. The hematopoietic progenitor cell (HPC) is an easily accessible cell type with glioma tropism 12 .
Systemically injected human peripheral blood-derived and murine bone marrow-derived
HPCs are attracted specifically to experimental gliomas through transforming growth factor (TGF)-β and stromal cell-derived factor-1α (SDF-1α)/CXC chemokine ligand 12-dependent migration and homing 12 . Tumour endothelial cells express E-selectin (CD62E), which is critical for HPC homing to gliomas by mediating adhesion of circulating HPCs to glioma endothelium 43 . Hypoxia, cerebral irradiation, and chemotherapy (TMZ) further enhance HPC attraction to tumour cells, suggesting that a combined treatment approach by HPCs and irradiation and/or chemotherapy may be advantageous 44 .
Implanted human skin-derived stem cells can migrate to experimental gliomas in which the cells reduce tumour angiogenesis and adopt a pericytic phenotype. The effects on glioma growth and prolonged animal survival indicate that skin-derived cells may be an autologous alternative for stem cell therapy of gliomas 45 .
Furthermore, systemically injected endothelial progenitor cells can home to experimental gliomas and integrate into the tumour vasculature 46, 47 . Therapeutic anti-glioma effects have been achieved by injecting endothelial progenitor cells that have been modified to produce oncolytic measles virus 48 or engineered to express cytotoxic antitumor genes 46 .
Embryonic stem cell-derived astrocytes have shown intracranial migratory capacity and therapeutic efficacy following implantation into subcutaneously established gliomas 49 . NSCs generated from induced pluripotent stem (iPS) cells have also been used as vectors in glioma gene therapy 50 ; however, compared to the other cell vectors described above, the clear advantages of using iPS cells for glioma gene therapy have not yet been demonstrated.
Thus, different types of stem and progenitor cells have been utilised for glioma gene therapy, and each cell type has advantages and disadvantages. There are at least three critical requirements that cell carriers should meet: 1) neoplasm-specific extensive migration within the glioma and to infiltrative GBM cells; 2) stable production and delivery of an oncolytic substance; and 3) implanted cells should not cause any substantial harm to the surrounding brain parenchyma. However, studies comparing migratory potential, proliferative capacity, cell survival, and delivery efficacy of different cellular vectors implanted into intracranial gliomas are lacking and highly warranted.
MECHANISMS OF MIGRATION
Neural stem cells and MSCs have been delivered to orthotopic glioma in preclinical studies by various routes of administration. The different ways to administer therapeutic stem cells to gliomas include direct implantation into tumours, intracerebral injection at a site located at a distance from the tumour, in the contralateral hemisphere, intracerebroventricular deposition, intravenous and intra-arterial injections 9, 10, 19, 21, 51, 52 . Although intratumoral MSC grafting can yield effective and tumour-selective distribution 13 , in terms of efficacy and safety, it is not clear which is the preferred route of administration.
A schematic overview of the tumour components regulating stem cell migration is given in
Inflammatory-derived factors can attract NSCs and MSCs to glioma. The peritumoral oedema zone in glioma is characterised by a high number of activated astrocytic and microglial cells and constitutes an inflammatory tumour microenvironment 53 . Several factors, notably interleukin (IL)-8 54 , monocyte chemotactic protein (MCP)-1 55 , and stromal derived factor-1 alpha (SDF-1α) 56 , are present within glioma or in the peritumoral reactive region and have been implicated in MSC migration to tumours. For instance, tumour necrosis factor-α can enhance the expression of CXC chemokine receptor (CXCR) 4 on MSCs, which results in increased MSC migration towards stroma-derived SDF-1α 57 . MCP-1 expression in gliomas can mediate glioma-tropic migration of NSCs through the CC chemokine receptor 2 58 .
Therapeutic irradiation produces an inflammatory response, and MSC tropism to the glioma is increased following brain irradiation 59, 60 . The irradiation-enhanced MSC tumour tropism is mediated in part by an increased IL-8 production from irradiated gliomas and CXCR1 upregulation on migratory MSCs 59 . Further information describing MSC migration to the inflammatory components of tumours is detailed by Spaeth et al. 61 .
In addition to inflammation, tumour angiogenesis and angiogenic signalling molecules influence MSC tropism to neoplasms. Findings from in vitro assays suggest that plateletderived growth factor (PDGF)-BB, PDGF-D, vascular endothelial growth factor (VEGF)-A, TGF-β1, and neurotrophin-3, all of which are involved in tumour angiogenesis, mediate MSC recruitment to gliomas 10, 62, 63 . Intratumorally grafted MSCs exhibit a marked tropism to tumour vasculature following intratumoral grafting, integrate into tumour vessel walls, and display a pericyte-like phenotype 13 . Tumour angiogenic signalling factors may also regulate MSC migration intratumorally in vivo 13 . Glioma angiogenesis inhibition, by the antiangiogenic drug sunitinib, substantially decreased the migration of grafted MSCs to tumours, indicating that tumour angiogenesis is critical for MSC intratumoral migration 13 . Angiogenic signalling has also been demonstrated to be important for NSC tracking of glioma cells 64 . The dependence on ongoing angiogenic signalling may confer a powerful glioma specificity to grafted, migratory stem cells because there is no active angiogenesis in the surrounding normal brain. Hypoxia upregulates CXCR4, urokinase plasminogen activator (uPA) receptor, and VEGF receptor 2 on NSCs, which enhances their migration towards gliomas 65 . These findings, in combination with the observed localisation of injected NSCs close to hypoxic areas within experimental gliomas, suggest that hypoxia is a critical factor for NSC tropism for gliomas 65 .
The migrating MSCs interact with and remodel the extracellular matrix (ECM) during migration. Matrix metalloproteinase (MMP)-1, a matrix-degrading enzyme, is upregulated specifically in MSCs, displaying a high propensity for glioma-directed migration. Conversely, overexpression of MMP-1 on relatively immobile subpopulations of MSCs increase their migration towards gliomas 66 . The composition of the glioma-derived ECM also influences NSC migration towards infiltrating glioma cells 67 .
Interestingly, molecules involved in chemotaxis during normal development are upregulated in malignant brain tumours and augment NSC and MSC tropism. Human NSCs are attracted to glioma cell-derived factors (hepatocyte growth factor, epidermal growth factor (EGF) and VEGF, uPA, and uPA receptor). It has been suggested that NSCs and migratory glioma cells use the same or similar pathways to enable their motility 68 .
Most mechanistic findings underlying NSC and MSC glioma tropism have been derived from in vitro experiments. These results have to be interpreted with caution because the in vivo tumour microenvironment is much more complex compared to the artificial in vitro microenvironment. Nevertheless, in vitro mechanistic knowledge responsible for NSC and MSC tumour tropism has been exploited to increase the efficacy of brain tumour homing for therapeutic purposes. EGF receptor overexpression on MSCs increases their infiltration into EGF-expressing gliomas 69 . Similarly, CXCR3 overexpressing HiB5 neural progenitor cells (NPCs) exhibit enhanced in vivo migration towards rat gliomas compared to non-transduced HiB5 cells 70 .
ANTI-TUMOR SUBSTANCE DELIVERY
Pro-inflammatory cytokines
A variety of cytokines have been delivered by NSCs or MSCs to gliomas and have demonstrated therapeutic efficacy alone or in combination with other treatment modalities 10, 17, 71, 72 . Early work demonstrated the therapeutic effects of implanting IL-4-producing NSCs on murine glioma growth 16 . Notably, the effects of NSC-produced IL-4 were more powerful than the virus-mediated transfer of IL-4 16 . Interleukin-mediated effects are related to a proinflammatory reaction, including an increased infiltration of anti-tumour immune cells (e.g., 71, 72 . The anti-tumour immune response can be further enhanced by combining the intratumoral implantation of cytokine-producing MSCs with systemic immunotherapy 72 .
CD4+ and CD8+ cytotoxic T-cells and natural killer cells) into tumours
Tumour necrosis factor-related apoptosis-inducing ligand
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) activates the pro-apoptotic death receptors (DRs) 4 and 5, which induce caspase-8-dependent apoptosis 73 . TRAIL can selectively target tumour cells while sparing most non-malignant cells 74 . TRAIL-producing NSC implantation into human gliomas in mice leads to increased tumour apoptosis and decreased tumour growth. However, the normal neural cells do not undergo apoptosis 75 .
Several studies have shown the therapeutic and tumour-specific effects by intracranially implanting or intravenously injecting TRAIL-producing MSCs 37, 76, 77, 78 , NPCs 79 , or ESCderived astrocytes 49 into experimental gliomas.
PEX
PEX is a human MMP-2 fragment that exerts anti-tumour effects by inhibiting glioma angiogenesis and tumour cell proliferation 80 . The intracranial implantation of human immortalised NSCs that are modified to produce PEX leads to decreased tumour vascularisation and tumour cell proliferation, resulting in an inhibited glioma growth 18 .
Pro-drug converting enzymes ("suicide" gene therapy)
Enzymes capable of converting inactive pro-drugs into toxic substances have been widely used in clinical glioma gene therapy. The intratumoral transfer of herpes simplex virus type 1 thymidine kinase (HSV-tk) in combination with the pro-drug ganciclovir (GCV) is the most extensively studied system. HSV-tk phosphorylates the guanosine analogue GCV, which is then incorporated into the DNA strand, leading to disturbed DNA synthesis and cell death.
The activated GCV is toxic to the HSV-tk-producing cells and the cells in their vicinity. This is due to a bystander effect, exerted by gap junctions between the cells through which the phosphorylated pro-drug is transported 81 . In clinical trials, HSV-tk has been transferred to tumours mainly using viral gene vectors. A phase III multicenter randomized clinical trial including 248 GBM patients showed no significant difference in survival between the HSV-tk gene therapy group and control group 82 . HSV-tk clinical gene therapy studies are reviewed by Pulkkanen et al. 7 . It was shown that the therapeutic effects were poor due to a low transduction efficiency of tumour cells in vivo and an ineffective vector distribution within the tumours 7 . Consequently, migratory stem cell vectors have been introduced in preclinical studies to achieve a better intratumoral distribution of the pro-drug converting enzyme.
Indeed, HSV-tk transfer using bone marrow-derived progenitor cells 83 , NSCs 84, 85 , and MSCs 52 , can lead to therapeutic effects through bystander-mediated glioma cell killing 83, 85, 86 .
Another well-investigated pro-drug activating enzyme is cytosine deaminase (CD), which converts 5-fluorocytosine (5-FC) to its toxic form, 5-fluorouracil, causing cell death 87 . CDexpressing NSCs have been used to treat intracranial rat gliomas 9 or human medulloblastomas in immunocompromised mice 88 . In 2010, a clinical pilot trial using immortalised NSCs engineered to produce CD in combination with oral 5-FC was initiated for patients undergoing surgery for recurrent high-grade gliomas. The aim of the study is to clarify the safety and feasibility of intracerebral NSC implantation and systemic 5-FC administration in glioma patients (ClinicalTrials.gov; Identifier: NCT01172964). Obviously, two critical issues for achieving therapeutic effects are the distribution of the pro-drug converting enzyme (i.e., administered stem cells) to the invasive glioma and the magnitude of the bystander effect in vivo.
Oncolytic viruses
In oncolytic virotherapy, viruses with the capacity to infect tumour cells are delivered systemically or locally to tumours. The viruses replicate within and lyse the tumour cells, whereby they are released for subsequent uptake by the neighbouring tumour cells. Although oncolytic virotherapy has delivered promising preclinical results, there are several obstacles for a successful clinical translation. First, viral particle delivery throughout the tumour tissue and to invasive tumour cells has been difficult. Second, the host immune system can attack and neutralise the viral particles before they can exert any effect 89 . It is possible to deliver viral particles to distant parts of the tumour using tumour-tropic migratory cells as oncolytic virus carriers. Furthermore, the viral particles within cells may be protected from the immune system 90 . NSCs, MSCs, and adipose-derived stem cells have been used for delivering oncolytic viruses (e.g., a conditionally replicating adenovirus) to experimental gliomas. These results suggest that stem cell-mediated oncolytic virus delivery is superior to viral delivery alone for the survival of glioma-bearing animals 22, 91-94 .
Antibodies
The administration of engineered stem cells may be an effective way to sustain local antitumour antibody delivery. Furthermore, stem-cell-based delivery of antibodies has the potential to reduce the toxic side-effects caused by intravenous antibody administration 95 . Coinjection of human glioma xenografts and human MSCs transfected to express a cell surfacebound single-chain antibody (scFv) against the EGF receptor variant III results in reduced tumour vascularisation and increased survival of glioma-bearing mice 96 . Table 1 summarises selected stem cell-based glioma therapy studies.
TOWARDS AN EFFECTIVE STEM CELL-BASED THERAPY FOR MALIGNANT
GLIOMA
The tumour-tropic migration of human, rat, and mouse NSCs and MSCs is associated with general GBM features (e.g., neovascularisation, inflammation, and growth factor production) and, importantly, are not animal model-specific. Therefore, it is conceivable that implanted human stem and precursor cells will migrate within the vascularised tumours of patients. A prospect for stem cell-based therapy for treating glioma patients includes implanting genetically modified stem cells into the remaining tumour after a surgical resection. One alternative could be to inject stem cells at multiple sites to target as many distant tumour satellites as possible. Subsequent stem cell implantations could be performed at later times using image-guided stereotaxic techniques. Irradiation can enhance tumour-tropic stem cell migration; therefore, a combined treatment with stem cells and radiotherapy may be effective 59, 60 .
However, even though the basic findings support the use of stem cell vectors in tumour therapy, numerous hurdles should be overcome. Here, we outline the future advancements in four areas, which will be important for clinical cell therapy development for glioma treatment.
Stem cell biology
The divergent results obtained from studying the interaction between stem cells, in particular MSCs, and tumour cells (discussed previously and reviewed by Klopp et al. 41 ) highlights the need for further studies on stem cell biology and the interplay between stem cells and gliomas in vivo. It is crucial to characterise the different MSC populations and to elucidate how they function with GBM tumor and stromal cells. Similarly, a deeper understanding of the interaction between NSCs and GBM tissue can lead to a safer and more effective stem cellbased therapy against gliomas.
Animal models
Preclinical results have been obtained from the use of glioma animal models that have been established only a few days prior to the initiation of treatment. The results derived from such studies can be valuable; currently, however, the experimental glioma features do not necessarily resemble the complex GBM characteristics in a patient. To show the clinical potential, experimental studies need to be designed in a "clinical time frame" manner. In particular, it is important to develop effective experimental stem cell-based therapies against glioma animal models that are highly infiltrative, vascularised and cellularly and genetically heterogeneous at the onset of treatment.
Choice of cell type and transgene
It is difficult to compare the results of many of the preclinical studies because there are important differences in the experimental settings. Thus, it would be valuable to systematically compare the migratory capacity and the long-term fate (i.e., proliferation and survival) of the different tumour-tropic cell types in glioma models. Similarly, the choice of stem cell-delivered therapeutic transgenes should be evaluated in a more systematic and comparative way. The results from such studies would provide valuable information when planning clinical trials.
Imaging
Non-invasive imaging will be important for following the migration and survival of implanted/injected stem cells into gliomas. Bioluminescence imaging, magnetic resonance imaging and positron emission tomography have been used to detect the administered stem cells in glioma animal models 21, 23, 83 . The different imaging modalities will provide information concerning the long-term fate of the implanted stem cells. Further technological improvements can provide a higher spatial resolution with the potential to trace stem cells at the single-cell level within gliomas.
CONCLUSIONS
Stem cell vectors may, by their capacity to target infiltrative tumour cells, provide a powerful treatment modality for GBM. However, many issues, including the choice of cell vector, choice of therapeutic transgene, the optimal route of administration and biosafety, need to be addressed. In light of the previous difficulties in translating experimental glioma therapy into successful clinical therapy, researchers should make a systematic and concerted effort to further examine the problems and the possibilities associated with stem cell vectors in order to clarify their clinical potential. 
